“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in SEK
Last close As at 28/03/2023
SEK6.29
— 0.00 (0.00%)
Market capitalisation
SEK1,108m
Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on NSCLC and pancreatic cancer. The most advanced trial is in Phase II.
Increasing understanding of inflammation in malignant processes now includes findings that cytokines are not only produced by the immune cells, but that cancer itself can produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent a potentially promising class of targets in oncology.
Managing Director - Head of Content, Healthcare
Goran Forsberg
CEO
Forecast net cash (SEKm)
119.4
Forecast gearing ratio (%)
N/A
Cantargia is a clinical-stage biotechnology company with lead asset nadunolimab (CAN04) under assessment for several oncology indications. The company has announced that the first triple-negative breast cancer patient has been treated in the Phase II part of the TRIFOUR trial. The Phase Ib portion showed a favourable safety profile of the drug with early signs of efficacy. The Phase II portion is an open-label, randomised trial to compare nadunolimab in combination with chemotherapy agents gemcitabine and carboplatin against the chemotherapy agents alone (expected n=98). We view this as an important milestone for Cantargia and management expects an interim futility analysis of 28 patients to take place in Q423.
| Y/E Dec | Revenue (SEKm) | EBITDA (SEKm) | PBT (SEKm) | EPS (öre) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 0.0 | (366.8) | (366.5) | (365.80) | N/A | N/A |
| 2022A | 0.0 | (377.9) | (371.8) | (290.43) | N/A | N/A |
| 2023E | 0.0 | (302.1) | (306.6) | (183.58) | N/A | N/A |
| 2024E | 0.0 | (286.9) | (292.6) | (175.20) | N/A | N/A |
